WVP
ESPR

Worth Venture Partners’s Esperion Therapeutics ESPR Stock Holding History

Worth Venture Partners’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-10
Closed -$1K – 100
2018
Q1 		$1K Buy
+10
New +$734 ﹤0.01% 103

Other funds holding ESPR

BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Worth Venture Partners's ESPR Position: Q2 2018 in Review

Worth Venture Partners sold out of Esperion Therapeutics (ESPR) in Q2 2018, closing a stake of 10 shares — an estimated $1K sold.

Worth Venture Partners first reported a position in ESPR in Q1 2018 and held it in 1 quarter. The position peaked at $1K in Q1 2018. 156 funds tracked by Wall St. Rank hold ESPR as of Q2 2018.

  • Worth Venture Partners reported no remaining Esperion Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Worth Venture Partners sold 10 Esperion Therapeutics shares in Q2 2018, an estimated $1K.
  • Worth Venture Partners first reported a position in Esperion Therapeutics in Q1 2018 and held it in 1 quarter.
  • Worth Venture Partners's Esperion Therapeutics position peaked at $1K in Q1 2018.
  • 156 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2018.

Based on Worth Venture Partners's 13F filing for Q2 2018, filed 13 Aug 2018.